文献速递淋巴瘤造血干细胞移植与细胞治疗

CAR-T细胞受者中的T细胞淋巴瘤:风险评估与因果性探讨

T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.
PubMed 文献 · Blood · 2024-01-01

2023年11月FDA公告报告了接受CAR-T治疗B细胞恶性肿瘤后发生继发性T细胞淋巴瘤的病例,引发广泛关注。本文综述现有信息,包括3例肿瘤细胞中检出克隆性CAR载体插入但无明确致癌证据的病例、其他未检出载体的病例,以及流行病学分析和机构长期队列研究,提示CAR-T后T细胞淋巴瘤风险极低。

要点

  • 3例继发性T细胞淋巴瘤患者肿瘤细胞中检出克隆性CAR载体插入,但无证据表明插入导致恶性转化。
  • 流行病学分析和机构长期CAR-T受者队列研究提示CAR-T后T细胞淋巴瘤风险极低。
  • 免疫功能障碍和克隆性造血可能在CAR-T后继发性恶性肿瘤中起更大作用。

核心结论

  • 现有证据提示CAR-T治疗后发生T细胞淋巴瘤的风险极低,载体插入性致癌作用缺乏明确证据。

研究设计与样本

  • 本文为综述,汇总截至目前的临床和分子病例报告、流行病学分析及机构长期CAR-T受者队列研究,并回顾既往关于成熟T细胞对插入性致癌易感性及HIV感染后T细胞转化的研究。

主要发现

  • 3例病例显示肿瘤细胞中存在克隆性CAR载体插入,但无明确证据表明这些插入在致癌转化中起作用。
  • 另有多例报告在肿瘤细胞中未检测到载体。
  • 流行病学分析和机构长期CAR-T受者队列研究提示CAR-T治疗后T细胞淋巴瘤风险极低。
  • 既往研究提示成熟T细胞对插入性致癌的易感性低,且自然HIV感染后几乎未见T细胞转化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The US Food and Drug Administration announcement in November 2023 regarding reports of the occurrence of secondary T-cell lymphomas in patients receiving chimeric antigen receptor T cells (CAR-Ts) for B-cell malignancies resulted in widespread concern among patients, clinicians, and scientists. Little information relevant to assessing causality, most importantly whether CAR retroviral or lentiviral vector genomic insertions contribute to oncogenesis, was initially available. However, since that time, several publications have provided clinical and molecular details on 3 cases showing clonal CAR vector insertions in tumor cells but without firm evidence these insertions played any role in oncogenic transformation. In addition, several other cases have been reported without vector detected in tumor cells. In addition, epidemiologic analyses as well as institutional long-term CAR-T recipient cohort studies provide important additional information suggesting the risk of T-cell lymphomas after CAR-T therapies is extremely low. This review will provide a summary of information available to date, as well as review relevant prior research suggesting a low susceptibility of mature T cells to insertional oncogenesis and documenting the almost complete lack of T-cell transformation after natural HIV infection. Alternative factors that may predispose patients treated with CAR-Ts to secondary hematologic malignancies, including immune dysfunction and clonal hematopoiesis, are discussed, and likely play a greater role than insertional mutagenesis in secondary malignancies after CAR therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hu J, Dunbar CE. T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities. Blood. 2024. PMID: 39393068. doi:10.1182/blood.2024025828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。